Q-omics provides the consensus-scored CACNA1I profile across patient tissues and cancer cell-line models. CACNA1I expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CACNA1I is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CACNA1I RNA expression shows 15,073 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, THCA, and THYM as cancer lineages where CACNA1I shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1I — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1I survival associations across molecular data types. CACNA1I RNA expression shows survival associations in the most cancer types (20), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1I RNA expression–survival associations across cancer types. High CACNA1I expression shows unfavorable associations in OV, UVM and STAD, but favorable associations in SKCM, BLCA and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CACNA1I RNA expression.
This table summarizes CACNA1I tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1I. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1I shows lower tumor expression in THCA and higher tumor expression in LUAD, KICH, BRCA, KIRC and UCEC. The THCA box plot shows higher CACNA1I RNA expression in normal versus tumor tissue (log2 FC = −1.047, t-test p < 0.001).
This table shows molecular features associated with CACNA1I in patient tissues and cancer cell lines. In patient samples, CACNA1I shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA1I RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
